These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 21312396)

  • 1. Antipsychotics and metabolics in the post-CATIE era.
    Meyer JM
    Curr Top Behav Neurosci; 2010; 4():23-42. PubMed ID: 21312396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interpreting and Applying the CATIE Results: With CATIE, context is key, when sorting out Phases 1, 1A, 1B, 2E, and 2T.
    Citrome L
    Psychiatry (Edgmont); 2007 Oct; 4(10):23-9. PubMed ID: 20428308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1.
    Meyer JM; Davis VG; Goff DC; McEvoy JP; Nasrallah HA; Davis SM; Rosenheck RA; Daumit GL; Hsiao J; Swartz MS; Stroup TS; Lieberman JA
    Schizophr Res; 2008 Apr; 101(1-3):273-86. PubMed ID: 18258416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.
    Meyer JM; McEvoy JP; Davis VG; Goff DC; Nasrallah HA; Davis SM; Hsiao JK; Swartz MS; Stroup TS; Lieberman JA
    Biol Psychiatry; 2009 Dec; 66(11):1013-22. PubMed ID: 19640511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study.
    Grossman I; Sullivan PF; Walley N; Liu Y; Dawson JR; Gumbs C; Gaedigk A; Leeder JS; McEvoy JP; Weale ME; Goldstein DB
    Genet Med; 2008 Oct; 10(10):720-9. PubMed ID: 18813134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical Antipsychotic Exposure May Not Differentiate Metabolic Phenotypes of Patients with Schizophrenia.
    Ward KM; Yeoman L; McHugh C; Kraal AZ; Flowers SA; Rothberg AE; Karnovsky A; Das AK; Ellingrod VL; Stringer KA
    Pharmacotherapy; 2018 Jun; 38(6):638-650. PubMed ID: 29722909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted pharmacogenetic analysis of antipsychotic response in the CATIE study.
    Liu Q; Jamba M; Patrick C; Padmanabhan S; Brennan MD
    Pharmacogenomics; 2012 Aug; 13(11):1227-37. PubMed ID: 22920393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guideline adherence for cardiometabolic monitoring of patients prescribed antipsychotic medications in primary care: a retrospective observational study.
    Ali RA; Jalal Z; Johal J; Paudyal V
    Int J Clin Pharm; 2023 Oct; 45(5):1241-1251. PubMed ID: 37755643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Latent class analysis of discordance between results of drug use assessments in the CATIE data.
    Johnson KL; Desmarais SL; Swartz MS; Van Dorn RA
    Schizophr Res; 2015 Feb; 161(2-3):434-8. PubMed ID: 25476120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schizophrenia and epileptic comorbidity.
    Drapier D
    Rev Neurol (Paris); 2024 Apr; 180(4):308-313. PubMed ID: 38503587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ranking tailoring variables for constructing individualized treatment rules: an application to schizophrenia.
    Wu J; Galanter N; Shortreed SM; Moodie EEM
    J R Stat Soc Ser C Appl Stat; 2022 Mar; 71(2):309-330. PubMed ID: 38288004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physical health monitoring for people with schizophrenia.
    Castle D; Li A
    Aust Prescr; 2023 Dec; 46(4):75-79. PubMed ID: 38152317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new era of rationally designed antipsychotics.
    Sibley DR; Shi L
    Nature; 2018 Mar; 555(7695):170-172. PubMed ID: 29517027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Research on antipsychotics in India.
    Avasthi A; Aggarwal M; Grover S; Khan MK
    Indian J Psychiatry; 2010 Jan; 52(Suppl 1):S317-40. PubMed ID: 21836703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of antipsychotics and mood stabilisers on metabolism in bipolar disorder: a network meta-analysis of randomised-controlled trials.
    Kong L; Wang H; Yan N; Xu C; Chen Y; Zeng Y; Guo X; Lu J; Hu S
    EClinicalMedicine; 2024 May; 71():102581. PubMed ID: 38618207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic proxies for antihypertensive drugs and mental disorders: Mendelian randomization study in European and East Asian populations.
    Fan B; Zhao JV
    BMC Med; 2024 Jan; 22(1):6. PubMed ID: 38166843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of the metabolic syndrome and associated factors among inpatients with severe mental illness in Botswana: a cross-sectional study.
    Tsima BM; Opondo P; Mosepele M; Mautle E; Bilker WB; Gross R
    BMC Cardiovasc Disord; 2022 Dec; 22(1):515. PubMed ID: 36460970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies.
    Dedic N; Dworak H; Zeni C; Rutigliano G; Howes OD
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study.
    Galderisi S; De Hert M; Del Prato S; Fagiolini A; Gorwood P; Leucht S; Maggioni AP; Mucci A; Arango C
    Eur Psychiatry; 2021 Jan; 64(1):e7. PubMed ID: 33413701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Model for Advancing Scale-Up of Complex Interventions for Vulnerable Populations: the ALACRITY Center for Health and Longevity in Mental Illness.
    McGinty EE; Murphy KA; Dalcin AT; Stuart EA; Wang NY; Dickerson F; Gudzune K; Jerome G; Thompson D; Cullen BA; Gennusa J; Kilbourne AM; Daumit GL
    J Gen Intern Med; 2021 Feb; 36(2):500-505. PubMed ID: 32869192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.